In summary, serum GRN was validated to be strongly upregulated in CLL and associated with an increased risk for disease progression and death, but GRN did not affect CLL cells or CLL accessory cells in vitro, and there was no evidence that it functionally drives the disease in vivo. Here, GRN is linked to B-cell chronic lymphocytic leukemia.